Biogen Media |

All Press Releases

Biogen Enrolls First Patient in Global Phase 3 Study of Investigational Treatment Aducanumab (BIIB037) for Early Alzheimer’s Disease
9/8/15 7:30 am EDT
USPTO Dismisses Inter Partes Review Petition of Biogen’s Patent 514 for TECFIDERA® (Dimethyl Fumarate)
9/2/15 5:05 pm EDT
Biogen, the ALS Association and Columbia University Medical Center Collaborate to Drive Understanding of Genetic Influence in ALS
8/18/15 7:00 am EDT
Results from B-YOND Extension Study Reinforce Long-Term Clinical Profile of ALPROLIX for the Treatment of Hemophilia B
8/17/15 7:00 am EDT
Extension Study Data Supporting Long-Term Safety and Efficacy of Eloctate® Published in Haemophilia
8/10/15 7:00 am EDT
Biogen Enters Collaboration with the Parkinson’s Institute and Clinical Center
7/27/15 7:30 am EDT
Biogen Second Quarter 2015 Revenues Increase 7% to $2.6 Billion
7/24/15 6:50 am EDT
Biogen Presents New Data from Phase 1B Study of Investigational Alzheimer’s Disease Treatment Aducanumab (BIIB037) at Alzheimer’s Association International Conference® 2015
7/22/15 6:45 am EDT
Douglas Williams to Leave Biogen for Biotechnology Start-Up
7/10/15 11:35 am EDT
Biogen to Report Second Quarter 2015 Financial Results on July 24, 2015
7/6/15 8:51 pm EDT

Biogen Enrolls First Patient in Global Phase 3 Study of Investigational Treatment Aducanumab (BIIB037) for Early Alzheimer’s Disease
9/8/15 7:30 am EDT
USPTO Dismisses Inter Partes Review Petition of Biogen’s Patent 514 for TECFIDERA® (Dimethyl Fumarate)
9/2/15 5:05 pm EDT
Biogen, the ALS Association and Columbia University Medical Center Collaborate to Drive Understanding of Genetic Influence in ALS
8/18/15 7:00 am EDT
Results from B-YOND Extension Study Reinforce Long-Term Clinical Profile of ALPROLIX for the Treatment of Hemophilia B
8/17/15 7:00 am EDT
Extension Study Data Supporting Long-Term Safety and Efficacy of Eloctate® Published in Haemophilia
8/10/15 7:00 am EDT
Biogen Enters Collaboration with the Parkinson’s Institute and Clinical Center
7/27/15 7:30 am EDT
Biogen Second Quarter 2015 Revenues Increase 7% to $2.6 Billion
7/24/15 6:50 am EDT
Biogen Presents New Data from Phase 1B Study of Investigational Alzheimer’s Disease Treatment Aducanumab (BIIB037) at Alzheimer’s Association International Conference® 2015
7/22/15 6:45 am EDT
Douglas Williams to Leave Biogen for Biotechnology Start-Up
7/10/15 11:35 am EDT
Biogen to Report Second Quarter 2015 Financial Results on July 24, 2015
7/6/15 8:51 pm EDT